Affinivax is creating novel vaccines that provide the highest level of protection against challenging infectious diseases, based on its proprietary vaccine technology platform.
Alkermes applies its scientific expertise and technological know-how to develop innovative medicines designed to help patients with serious, chronic conditions better manage their disease.
Alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as RNA interference, or RNAi.
Alzheon is a clinical-stage biotechnology company focused on brain health, memory and aging, developing innovative treatments for Alzheimer’s disease and other neurodegenerative disorders.
Tarveda Therapeutics takes a novel approach to cancer treatment by creating Pentarins™, which are miniaturized biologic drug conjugates uniquely designed to target, penetrate and treat solid tumors.
Concert Pharmaceuticals uses deuterium-based chemistry to create and develop highly differentiated new medicines by leveraging decades of pharmaceutical and clinical experience to reduce time, risk, and expense.
Deciphera Pharmaceuticals is focused on improved kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread.
Eleven Biotherapeutics creates first-of-a-kind protein-based drugs with significantly improved physical, pharmaceutical, and therapeutic benefits.
Emulate is using its Organs-on-Chips technology to create living products for understanding how diseases, medicines, chemicals, and foods affect human health.
Fibrocell is at the vanguard of the emerging field of personalized biologics, developing therapeutics that harness a person’s own cells to target localized treatment of rare and serious skin and connective tissue diseases.
Navitor is a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling via the mTORC1 pathway.
NextCODE Health is a sequence-based clinical diagnostics company delivering a powerful solution to genome interpretation and big data challenges.
Opsonix is developing pathogen-extracting therapies to transform the treatment of blood borne infectious diseases, including sepsis.
Promedior is developing a novel biology platform for the treatment of fibrosis, inflammation, and neovascular retinal diseases.
Scholar Rock is discovering and developing a new class of biologic therapies that target disease-causing proteins in the microenvironment, resulting in therapeutic effects specifically at the source of disease.
Selecta Biosciences is developing a new class of targeted vaccines that induce an antigen-specific immune activation or an antigen-specific immune tolerance for therapeutic and prophylactic application.
True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need.
Visterra is a biotechnology company that uses its Atomic Interaction Network analysis to identify unique disease targets and design effective therapeutics.